John Burke, MD, is a hematologist, medical oncologist, and blood cancer specialist at Rocky Mountain Cancer Centers.
The NCCN guidelines options available for patients with relapsed/refractory DLBCL include gemcitabine/oxaliplatin with or without rituximab, polatuzumab vedotin with or without bendamustine and rituximab, or the combination of bendamustine and rituximab alone.
John M. Burke, MD, of Rocky Mountain Cancer Centers, explains the rationale behind treating an elderly woman with relapsed diffuse large B-cell lymphoma with tafasitamab and lenalidomide after R-CHOP chemotherapy.
John M. Burke, MD, discusses treatment with rituximab versus obinutuzumab in patients with advanced stage follicular lymphoma with high tumor burden.